Five-year follow-up of a phase 2 RCT of ponatinib starting at 45, 30 or 15 mg daily in 283 patients with resistant or T315I-positive chronic-phase CML: ≤1% BCR::ABL1 reached 60%, 41% and 40%; 5-year PFS 63%, 57% and 60%.
RCTn = 283
Kantarjian et al. Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial